Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions

References

• JamesSL, AbateD, AbateKH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.30496104
   PubMed Web of Science ®Google Scholar
• LochmannD, RichardsonT. Selective serotonin reuptake inhibitors. Handb Exp Pharmacol. 2019;250:135–144.30838457
   PubMedGoogle Scholar
• MurdochD, KeamSJ. Spotlight on escitalopram in the management of major depressive disorder. CNS Drugs. 2006;20(2):167–170. doi:10.2165/00023210-200620020-0000716478291
   PubMed Web of Science ®Google Scholar
• BurkeWJ. Escitalopram. Expert Opin Investig Drugs. 2002;11(10):1477–1486. doi:10.1517/13543784.11.10.1477
   PubMed Web of Science ®Google Scholar
• SøgaardB, MengelH, RaoN, LarsenF. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. 2005;45(12):1400–1406. doi:10.1177/009127000528086016291715
   PubMed Web of Science ®Google Scholar
• RaoN. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281–290. doi:10.2165/00003088-200746040-0000217375980
   PubMed Web of Science ®Google Scholar
• AlmeidaS, PedrosoP, FilipeA, NevesRI, TanguayM, TornsA. Bioequivalence of two formulations of escitalopram. Arzneimittelforschung. 2012;62(7):307–312.22628062
   PubMed Web of Science ®Google Scholar
• MendesGD, BabadopulosT, BauFR, ChenLS, De NucciG. Comparative bioavailability of two escitalopram formulations in healthy human volunteers. Int J Clin Pharmacol Ther. 2010;48(8):554–562. doi:10.5414/CPP4855420650049
   PubMed Web of Science ®Google Scholar
• LepolaUM, LoftH, ReinesEH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18(4):211–217. doi:10.1097/01.yic.0000074988.54339.7c12817155
   PubMed Web of Science ®Google Scholar
• WadeA, DespiegelN, HeldboReinesE. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. 2006;18(2):83–89. doi:10.1080/1040123060061444716754413
   PubMedGoogle Scholar
• StahlSM, GergelI, LiD. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003;64(11):1322–1327. doi:10.4088/JCP.v64n110714658946
   PubMed Web of Science ®Google Scholar
• BoulengerJP, HuusomAK, FloreaI, BaekdalT, SarchiaponeM. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006;22(7):1331–1341. doi:10.1185/030079906X11551316834832
   PubMed Web of Science ®Google Scholar
• NgQX, YongCSK, LokeW, YeoWS, SohAYS. Escitalopram-induced liver injury: a case report and review of literature. World J Hepatol. 2019;11(10):719–724. doi:10.4254/wjh.v11.i10.71931749902
   PubMed Web of Science ®Google Scholar
• StickleyA, LeinsaluM, DeVylderJE, InoueY, KoyanagiA. Sleep problems and depression among 237 023 community-dwelling adults in 46 low- and middle-income countries. Sci Rep. 2019;9(1):12011. doi:10.1038/s41598-019-48334-731427590
   PubMed Web of Science ®Google Scholar
• JukićMM, HaslemoT, MoldenE, Ingelman-SundbergM. Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2087 patients. Am J Psychiatry. 2018;175(5):463–470. doi:10.1176/appi.ajp.2017.1705055029325448
   PubMed Web of Science ®Google Scholar
• ZhouL, SharmaP, YeoKR, et al. Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. Eur J Pharm Sci. 2019;139:105061. doi:10.1016/j.ejps.2019.10506131479720
   PubMed Web of Science ®Google Scholar
• ChenuF, BattenLA, ZernigG, LadstaetterE, HébertC, BlierP. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry. 2009;70(7):958–966. doi:10.4088/JCP.09m0531519653973
   PubMed Web of Science ®Google Scholar
• BareggiSR, MundoE, Dell’OssoB, AltamuraAC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007;3(5):741–753. doi:10.1517/17425255.3.5.74117916059
   PubMed Web of Science ®Google Scholar
• BishopJR, NajjarF, RubinLH, et al. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015;25(11):548–554.26313485
   PubMed Web of Science ®Google Scholar
• JiangT, RongZ, XuY, et al. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers. Clin Drug Investig. 2013;33(1):1–9. doi:10.1007/s40261-012-0010-8
   PubMed Web of Science ®Google Scholar
• de LeonJ, ArmstrongSC, CozzaKL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75–85. doi:10.1176/appi.psy.47.1.7516384813
   PubMed Web of Science ®Google Scholar
• ChenL, QinS, XieJ, et al. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 2008;9(6):691–702. doi:10.2217/14622416.9.6.69118518848
   PubMed Web of Science ®Google Scholar
• World Medical Association General Assembly. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15(1):124–129.15835069
   PubMedGoogle Scholar
• HoraiY, NakanoM, IshizakiT, et al. Metoprolol and mephenytoin oxidation polymorphisms in far eastern oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther. 1989;46(2):198–207. doi:10.1038/clpt.1989.1262758729
   PubMed Web of Science ®Google Scholar
• NilausenDØ, ZuikerRG, van GervenJ. The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Clin Ther. 2011;33(10):1492–1502.21999886
   PubMed Web of Science ®Google Scholar
• ArebergJ, ChristophersenJS, PoulsenMN, LarsenF, MolzKH. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J. 2006;8(1):E14–E19. doi:10.1208/aapsj08010216584121
   PubMed Web of Science ®Google Scholar
• AgarwalS, GowdaKV, SelvanPS, ChattarajTK, PalTK. Bioequivalence of two commercial preparations of escitalopram oxalate/clonazepam using a liquid chromatography-electrospray mass spectrometry method. Arzneimittelforschung. 2008;58(11):551–556.19137905
   PubMed Web of Science ®Google Scholar
• LiJ, TianY, ZhangZJ, WangN, RenX, ChenY. Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2009;59(5):228–232.19537522
   PubMed Web of Science ®Google Scholar
• SinghSS, ShahH, GuptaS, et al. Liquid chromatography–electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;811(2):209–215. doi:10.1016/S1570-0232(04)00703-2
   PubMed Web of Science ®Google Scholar